Intracellular p-CDK2 in Peripheral Blood NK Cells as a Biomarker for Primary Central Nervous System Lymphoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500110252

Enrollment

Unknown

Registered

2025-10-11

Start date

2025-10-13

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary central nervous system lymphoma

Interventions

patients with primary central nervous system lymphoma:None

healthy donors:None

Patients with diffuse large B-cell lymphoma without central nervous system involvement:None

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) age 18-75 years, male or female 2) diagnosed as primary central nervous system lymphoma; 3) Hospitalized in the Hematology Department of our hospital between April 1, 2025 and April 1, 2026.

Exclusion criteria

Exclusion criteria: 1)The lesions are confined solely to the intraocular region or cerebrospinal fluid, with no measurable intracranial lesions present.

Design outcomes

Primary

Measure	Time frame
p-CDK2;	—

Countries

China

Contacts

Public ContactLin Zhiguang

Huashan Hospital, Fudan University

zhiguang_lin@163.com+86 139 1792 9043

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026